Get the Stockscreener App
1.22
2.40%
-0.03
After Hours:
1.17
-0.05
-4.10%
Mira Pharmaceuticals Inc stock is traded at $1.22, with a volume of 207.46K.
It is down -2.40% in the last 24 hours and up +44.38% over the past month.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
207.46K
Relative Volume:
0.17
Market Cap:
$19.50M
Revenue:
-
Net Income/Loss:
$-11.24M
P/E Ratio:
-1.6021
EPS:
-0.7615
Net Cash Flow:
$-4.79M
1W Performance:
+5.17%
1M Performance:
+44.38%
6M Performance:
-22.29%
1Y Performance:
+62.67%
1-Day Range:
$1.17
$1.25
1-Week Range:
$1.03
$1.30
52-Week Range:
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.22 | 19.50M | 0 | -11.24M | -4.79M | -0.7615 |
|
LLY
Lilly Eli Co
|
734.57 | 739.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.22 | 375.64B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
184.60 | 351.09B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.77 | 307.32B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.70 | 225.73B | 53.22B | 12.86B | 14.85B | 6.39 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
MIRA Pharmaceuticals (MIRA) Projected to Post Earnings on Monday - Defense World
Why Mira Pharmaceuticals Inc (NASDAQ: MIRA) Is A Great Stock Pick For Momentum Investors - Stocksregister
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong By Stocktwits - Investing.com India
MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong - Asianet Newsable
MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60M - TipRanks
MIRA Pharmaceuticals to acquire SKNY in strategic move - Investing.com
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review - Corsicana Daily Sun
EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million - Yahoo Finance
Renaissance Technologies LLC Takes Position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity - The Joplin Globe
MIRA Achieves Positive Safety Results in Neurotoxicity Study | M - GuruFocus
EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study - AOL.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 - Investing.com
MIRA Pharmaceuticals reports safe profile for Ketamir-2 By Investing.com - Investing.com UK
MIRA Pharmaceuticals Completes Key Neurotoxicity Study for Ketamir-2 - TipRanks
Breakthrough: New Drug Outperforms Ketamine in FDA Brain Safety StudyZero Toxicity Detected - Stock Titan
Pharmaceutical Stock Jumps After Key Trial Findings - MSN
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 14.1% in April - Defense World
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Mira Pharmaceuticals Inc [MIRA] moved up 7.08: Why It’s Important - dbtnews.com
Financial Metrics Unveiled: Mira Pharmaceuticals Inc (MIRA)’s Key Ratios in the Spotlight - DWinneX
MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-2 - MSN
Mira Pharmaceuticals announces key drug development milestone By Investing.com - Investing.com Canada
Mira Pharmaceuticals announces key drug development milestone - Investing.com Australia
MIRA Pharmaceuticals (MIRA) Advances Ketamir-2 Formulations in P - GuruFocus
MIRA Pharmaceuticals reports positive Ketamir-2 study By Investing.com - Investing.com India
MIRA Pharmaceuticals reports positive Ketamir-2 study - Investing.com
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation - Weatherford Democrat
Press Release Distribution & PR Platform - ACCESS Newswire
MIRA's Novel Pain Treatment Delivers Positive Data, Targets Massive $11.5B Market With Fast-Track Potential - Stock Titan
Mira Pharmaceuticals Inc (MIRA) is a good investment, but the stock may be undervalued - uspostnews.com
MIRA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Promising Canadian Stocks To Follow Now – April 16th - Defense World
Is Mira Pharmaceuticals Gaining or Losing Market Support? - Benzinga
US Health Care Stocks Face Mixed Results With Sector's Broad Decline - Finimize
MIRA reports Ketamir-2 shows promise in diabetic neuropathy study By Investing.com - Investing.com South Africa
Mira Says Diabetes Treatment Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms in Animal Model - marketscreener.com
MIRA reports Ketamir-2 shows promise in diabetic neuropathy study - Investing.com Australia
MIRA Pharmaceuticals reports positive Ketamir-2 study results - Investing.com
MIRA Pharmaceuticals reports positive Ketamir-2 study results By Investing.com - Investing.com Canada
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion - Corsicana Daily Sun
Game-Changing Results: New Oral Ketamine Drug Outperforms FDA-Approved Pain Medications - Stock Titan
Mira Pharmaceuticals IncAnnounces Positive Study Results For Ketamir-2 - marketscreener.com
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study - Benzinga
Mira Pharmaceuticals faces Nasdaq delisting over equity - Investing.com Australia
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):